162 related articles for article (PubMed ID: 17504123)
1. MUC1 is a promising therapeutic target for prostate cancer therapy.
Li Y; Cozzi PJ
Curr Cancer Drug Targets; 2007 May; 7(3):259-71. PubMed ID: 17504123
[TBL] [Abstract][Full Text] [Related]
2. The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression.
Deng J; Wang L; Chen H; Li L; Ma Y; Ni J; Li Y
Cancer Metastasis Rev; 2013 Dec; 32(3-4):535-51. PubMed ID: 23609751
[TBL] [Abstract][Full Text] [Related]
3. MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer.
Cozzi PJ; Wang J; Delprado W; Perkins AC; Allen BJ; Russell PJ; Li Y
Clin Exp Metastasis; 2005; 22(7):565-73. PubMed ID: 16475027
[TBL] [Abstract][Full Text] [Related]
4. MUC1 is upregulated in advanced prostate cancer and is an independent prognostic factor.
Genitsch V; Zlobec I; Thalmann GN; Fleischmann A
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):242-7. PubMed ID: 27165976
[TBL] [Abstract][Full Text] [Related]
5. MUC1 expression, splice variant and short form transcription (MUC1/Z, MUC1/Y) in prostate cell lines and tissue.
Schut IC; Waterfall PM; Ross M; O'Sullivan C; Miller WR; Habib FK; Bayne CW
BJU Int; 2003 Feb; 91(3):278-83. PubMed ID: 12581019
[TBL] [Abstract][Full Text] [Related]
6. Advances of MUC1 as a target for breast cancer immunotherapy.
Yang E; Hu XF; Xing PX
Histol Histopathol; 2007 Aug; 22(8):905-22. PubMed ID: 17503348
[TBL] [Abstract][Full Text] [Related]
7. MUC1 oncoprotein is a druggable target in human prostate cancer cells.
Joshi MD; Ahmad R; Yin L; Raina D; Rajabi H; Bubley G; Kharbanda S; Kufe D
Mol Cancer Ther; 2009 Nov; 8(11):3056-65. PubMed ID: 19887552
[TBL] [Abstract][Full Text] [Related]
8. MUC1: a target molecule for cancer therapy.
Singh R; Bandyopadhyay D
Cancer Biol Ther; 2007 Apr; 6(4):481-6. PubMed ID: 18027437
[TBL] [Abstract][Full Text] [Related]
9. MUC1 in hematological malignancies.
Stroopinsky D; Kufe D; Avigan D
Leuk Lymphoma; 2016 Nov; 57(11):2489-98. PubMed ID: 27347699
[TBL] [Abstract][Full Text] [Related]
10. Aberrant expression of transmembrane mucins, MUC1 and MUC4, in human prostate carcinomas.
Singh AP; Chauhan SC; Bafna S; Johansson SL; Smith LM; Moniaux N; Lin MF; Batra SK
Prostate; 2006 Mar; 66(4):421-9. PubMed ID: 16302265
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer.
DeNardo SJ; Richman CM; Albrecht H; Burke PA; Natarajan A; Yuan A; Gregg JP; O'Donnell RT; DeNardo GL
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7187s-7194s. PubMed ID: 16203820
[TBL] [Abstract][Full Text] [Related]
12. Expression of sialylated MUC1 in prostate cancer: relationship to clinical stage and prognosis.
Arai T; Fujita K; Fujime M; Irimura T
Int J Urol; 2005 Jul; 12(7):654-61. PubMed ID: 16045558
[TBL] [Abstract][Full Text] [Related]
13. Combination of curcumin and bicalutamide enhanced the growth inhibition of androgen-independent prostate cancer cells through SAPK/JNK and MEK/ERK1/2-mediated targeting NF-κB/p65 and MUC1-C.
Li J; Xiang S; Zhang Q; Wu J; Tang Q; Zhou J; Yang L; Chen Z; Hann SS
J Exp Clin Cancer Res; 2015 May; 34(1):46. PubMed ID: 25971429
[TBL] [Abstract][Full Text] [Related]
14. Characterization of MUC1 glycoprotein on prostate cancer for selection of targeting molecules.
Burke PA; Gregg JP; Bakhtiar B; Beckett LA; Denardo GL; Albrecht H; De Vere White RW; De Nardo SJ
Int J Oncol; 2006 Jul; 29(1):49-55. PubMed ID: 16773184
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of MUC1 and Genomic Alterations in Its Network Associate with Prostate Cancer Progression.
Lin X; Gu Y; Kapoor A; Wei F; Aziz T; Ojo D; Jiang Y; Bonert M; Shayegan B; Yang H; Al-Nedawi K; Major P; Tang D
Neoplasia; 2017 Nov; 19(11):857-867. PubMed ID: 28930697
[TBL] [Abstract][Full Text] [Related]
16. Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma.
Henderikx P; Kandilogiannaki M; Petrarca C; von Mensdorff-Pouilly S; Hilgers JH; Krambovitis E; Arends JW; Hoogenboom HR
Cancer Res; 1998 Oct; 58(19):4324-32. PubMed ID: 9766660
[TBL] [Abstract][Full Text] [Related]
17. Anti-MUC1 aptamer: A potential opportunity for cancer treatment.
Nabavinia MS; Gholoobi A; Charbgoo F; Nabavinia M; Ramezani M; Abnous K
Med Res Rev; 2017 Nov; 37(6):1518-1539. PubMed ID: 28759115
[TBL] [Abstract][Full Text] [Related]
18. Targeting uPA/uPAR in prostate cancer.
Li Y; Cozzi PJ
Cancer Treat Rev; 2007 Oct; 33(6):521-7. PubMed ID: 17658220
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of GCNT1 is associated with altered O-glycosylation of PSA, PAP, and MUC1 in human prostate cancers.
Chen Z; Gulzar ZG; St Hill CA; Walcheck B; Brooks JD
Prostate; 2014 Jul; 74(10):1059-67. PubMed ID: 24854630
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of reactivity of anti-MUC1 core protein antibody and killing activity of anti-MUC1 cytotoxic T cells by deglycosylation of target tissues or cells.
Hinoda Y; Takahashi T; Hayashi T; Suwa T; Makiguchi Y; Itoh F; Adachi M; Imai K
J Gastroenterol; 1998 Apr; 33(2):164-71. PubMed ID: 9605944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
